ERBB2 and thyroid gland carcinoma: A number of studies [128,129,130] which assessed HER2 expression in thyroid cancer have shown that a substantial percentage exhibit the increased presence of HER2/3 receptors, with expression levels comprised between 40% (FTC) and 18% (PTC) [131], indicating HER2/3 as a potential therapeutic target.